Filters

Abiraterone manufacturers

29 products found

Filters

abiraterone

Tablets 250 mg, 500 mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Ready
GMP approvals
EU GMP
Unavailable markets
Vietnam

abiraterone

Tablets 250mg, 500mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Portugal, Vietnam

abiraterone

Tablets 250 mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
FDA,EU GMP,ANVISA,Libya,Saudi Arabia,South Korea
Unavailable markets
United States, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Malta, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, Yemen, Ethiopia, Sudan, Vietnam

abiraterone

Tablets 250mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Vietnam

abiraterone

Tablets, film coated 500 mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
FDA,EU GMP,ANVISA,Libya,Saudi Arabia,South Korea
Unavailable markets
Colombia, Saudi Arabia, Vietnam

abiraterone

Tablets 250mg, 500mg

Dossier type
EU CTD
Country of origin
Turkey
Dossier status
Under Development
GMP approvals
EU GMP

abiraterone

Tablets, film coated 250 mg, 500 mg

Dossier type
EU CTD
Country of origin
India
Dossier status
Ready
GMP approvals
EU GMP
Unavailable markets
Chile, Turkey, Vietnam, Panama

abiraterone

Tablets 250mg, 500mg

Dossier type
US CTD
Country of origin
Malaysia
Dossier status
Ready
Clinical data
Bioequivalence
GMP approvals
FDA
Unavailable markets
Malaysia, United States, Vietnam

abiraterone

Tablets, film coated 250mg, 500mg

Dossier type
US CTD
Country of origin
India
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Algeria, Vietnam, Iran

abiraterone

Tablets 250 mg

Dossier type
US CTD
Country of origin
India
Dossier status
Ready
GMP approvals
FDA

Abiraterone acetate Manufacturers

Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication. Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer. Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world. Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from: Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication. it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of <2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced. Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include: severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease like heart failure and hypertension, uncorrected hypokalemia,

How Does Abiraterone acetate Work?

Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.

The Wholesale Price of Abiraterone acetate

The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.

Sourcing Abiraterone Manufacturers and Abiraterone acetate Suppliers

Those who are looking for an easy and convenient way to source and order abiraterone may search online using Pipelinepharma's marketplace. Through our strict evaluation and quality control process, you are assured to find verified abiraterone manufacturers and suppliers.